Three molecules specifically designed for long duration of action*⁹⁻¹⁵
Learn more about fluticasone furoate (ICS), umeclidinium (LAMA) and vilanterol (LABA) and their specific mechanism of action.
Could simplified delivery of COPD triple therapy in a single inhaler make a difference for your patient?
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with
PM-GB-FVU-WCNT-200014 | September 2020